Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
An update from Artelo Biosciences ( (ARTL) ) is now available.
On August 28, 2025, Artelo Biosciences held a Special Meeting of Stockholders where 365,886 shares were represented. During the meeting, stockholders approved an amendment to increase the authorized number of common stock shares from 8,333,333 to 500,000,000. However, a proposal to increase the authorized number of preferred stock shares from 69,444 to 10,000,000 was not approved. Additionally, the appointment of Malone Bailey LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2025, was ratified.
The most recent analyst rating on (ARTL) stock is a Buy with a $20.00 price target. To see the full list of analyst forecasts on Artelo Biosciences stock, see the ARTL Stock Forecast page.
Spark’s Take on ARTL Stock
According to Spark, TipRanks’ AI Analyst, ARTL is a Underperform.
Artelo Biosciences faces substantial financial hurdles with no revenue and continuous losses, heavily impacting its overall score. Technical indicators do not show a strong recovery trend, and the lack of new guidance from earnings calls further adds uncertainty. Valuation metrics are unfavorable due to negative earnings, making the stock less appealing to investors.
To see Spark’s full report on ARTL stock, click here.
More about Artelo Biosciences
Average Trading Volume: 665,653
Technical Sentiment Signal: Hold
Current Market Cap: $11.95M
Learn more about ARTL stock on TipRanks’ Stock Analysis page.